• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Zealand Pharma

306.00 DKK

+3.45 %

Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.45 %
-1.48 %
+14.09 %
-34.39 %
-37.91 %
-32.21 %
+10.87 %
+51.79 %
+284.91 %

Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.

Read more
Market cap
21.9B DKK
Turnover
122.78M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
13.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release4 hours ago

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Zealand Pharma
Regulatory press release6/10/2026, 8:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release6/8/2026, 3:05 PM

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Zealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release6/8/2026, 3:00 PM

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
Regulatory press release6/7/2026, 6:30 PM

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Zealand Pharma
Regulatory press release6/1/2026, 3:00 PM

Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)

Zealand Pharma
Regulatory press release5/29/2026, 8:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release5/26/2026, 3:30 PM

Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)

Zealand Pharma
Regulatory press release5/26/2026, 2:00 PM

Resolutions from Zealand Pharma's Extraordinary General Meeting 2026

Zealand Pharma
Regulatory press release5/14/2026, 3:00 PM

Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)

Zealand Pharma
Regulatory press release5/7/2026, 5:05 AM

Zealand Pharma - Execution framework for share buy-back program

Zealand Pharma
Regulatory press release5/7/2026, 5:00 AM

Zealand Pharma Announces Financial Results for the First Three Months of 2026

Zealand Pharma
Regulatory press release5/7/2026, 4:55 AM

Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program

Zealand Pharma
Regulatory press release5/1/2026, 1:00 PM

Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026

Zealand Pharma
Regulatory press release4/29/2026, 5:01 PM

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

Zealand Pharma
Regulatory press release4/28/2026, 6:00 AM

Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial

Zealand Pharma
Regulatory press release4/22/2026, 8:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release4/19/2026, 8:05 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release4/19/2026, 8:00 PM

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026

Zealand Pharma
Regulatory press release3/31/2026, 8:00 PM

Total number of shares and voting rights in Zealand Pharma as of March 31, 2026

Zealand Pharma